432 related articles for article (PubMed ID: 21989859)
1. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
[TBL] [Abstract][Full Text] [Related]
2. Clinical and imaging markers in premotor LRRK2 G2019S mutation carriers.
Vilas D; Ispierto L; Álvarez R; Pont-Sunyer C; Martí MJ; Valldeoriola F; Compta Y; de Fabregues O; Hernández-Vara J; Puente V; Calopa M; Jaumà S; Campdelacreu J; Aguilar M; Quílez P; Casquero P; Lomeña F; Ríos J; Tolosa E
Parkinsonism Relat Disord; 2015 Oct; 21(10):1170-6. PubMed ID: 26306001
[TBL] [Abstract][Full Text] [Related]
3. A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Thaler A; Artzi M; Mirelman A; Jacob Y; Helmich RC; van Nuenen BF; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Hendler T; Giladi N; Ben Bashat D;
Mov Disord; 2014 May; 29(6):823-7. PubMed ID: 24482120
[TBL] [Abstract][Full Text] [Related]
4. Nigral and striatal connectivity alterations in asymptomatic LRRK2 mutation carriers: A magnetic resonance imaging study.
Vilas D; Segura B; Baggio HC; Pont-Sunyer C; Compta Y; Valldeoriola F; José Martí M; Quintana M; Bayés A; Hernández-Vara J; Calopa M; Aguilar M; Junqué C; Tolosa E;
Mov Disord; 2016 Dec; 31(12):1820-1828. PubMed ID: 27653520
[TBL] [Abstract][Full Text] [Related]
5. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
[TBL] [Abstract][Full Text] [Related]
6. Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Sierra M; Sánchez-Juan P; Martínez-Rodríguez MI; González-Aramburu I; García-Gorostiaga I; Quirce MR; Palacio E; Carril JM; Berciano J; Combarros O; Infante J
Neurology; 2013 Feb; 80(7):621-6. PubMed ID: 23325906
[TBL] [Abstract][Full Text] [Related]
7. High nigral iron deposition in LRRK2 and Parkin mutation carriers using R2* relaxometry.
Pyatigorskaya N; Sharman M; Corvol JC; Valabregue R; Yahia-Cherif L; Poupon F; Cormier-Dequaire F; Siebner H; Klebe S; Vidailhet M; Brice A; Lehéricy S
Mov Disord; 2015 Jul; 30(8):1077-84. PubMed ID: 26011561
[TBL] [Abstract][Full Text] [Related]
8. Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
Brüggemann N; Hagenah J; Stanley K; Klein C; Wang C; Raymond D; Ozelius L; Bressman S; Saunders-Pullman R
Mov Disord; 2011 Apr; 26(5):885-8. PubMed ID: 21312285
[TBL] [Abstract][Full Text] [Related]
9. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
[TBL] [Abstract][Full Text] [Related]
10. Motor phenotype of LRRK2-associated Parkinson's disease: a Tunisian longitudinal study.
Nabli F; Ben Sassi S; Amouri R; Duda JE; Farrer MJ; Hentati F
Mov Disord; 2015 Feb; 30(2):253-8. PubMed ID: 25487881
[TBL] [Abstract][Full Text] [Related]
11. Sex effects on clinical features in LRRK2 G2385R carriers and non-carriers in Parkinson's disease.
Cui SS; Fu R; Du JJ; Lin YQ; Huang P; Gao C; Zhou HY; Chen SD
BMC Neurosci; 2021 Mar; 22(1):22. PubMed ID: 33771108
[TBL] [Abstract][Full Text] [Related]
12. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
13. Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers.
Thaler A; Mirelman A; Helmich RC; van Nuenen BF; Rosenberg-Katz K; Gurevich T; Orr-Urtreger A; Marder K; Bressman S; Bloem BR; Giladi N; Hendler T;
Cortex; 2013 Oct; 49(9):2501-11. PubMed ID: 23357204
[TBL] [Abstract][Full Text] [Related]
14. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
[TBL] [Abstract][Full Text] [Related]
15. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?
Orr-Urtreger A; Shifrin C; Rozovski U; Rosner S; Bercovich D; Gurevich T; Yagev-More H; Bar-Shira A; Giladi N
Neurology; 2007 Oct; 69(16):1595-602. PubMed ID: 17938369
[TBL] [Abstract][Full Text] [Related]
16. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive LRRK2 and GBA screening in Portuguese patients with Parkinson's disease: identification of a new family with the LRRK2 p.Arg1441His mutation and novel missense variants.
Zhang L; Quadri M; Guedes LC; Coelho M; Valadas A; Mestre T; Lobo PP; Rosa MM; Simons E; Oostra BA; Ferreira JJ; Bonifati V
Parkinsonism Relat Disord; 2013 Oct; 19(10):897-900. PubMed ID: 23726462
[TBL] [Abstract][Full Text] [Related]
18. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
[TBL] [Abstract][Full Text] [Related]
19. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
[TBL] [Abstract][Full Text] [Related]
20. Subclinical signs in LRRK2 mutation carriers.
Johansen KK; White LR; Farrer MJ; Aasly JO
Parkinsonism Relat Disord; 2011 Aug; 17(7):528-32. PubMed ID: 21641848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
